首頁 > 市場調查報告書 > 製藥

生物製劑

重組蛋白市場規模、佔有率及成長分析（按產品、應用及地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1899232

重組蛋白市場規模、佔有率及成長分析（按產品、應用及地區分類）－2026-2033年產業預測

Recombinant Protein Market Size, Share, and Growth Analysis, By Product (Cytokines & Growth Factors, Antibodies), By Application (Drug Discovery & Development, Biopharmaceutical Production), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，重組蛋白市場規模將達到 25.3 億美元，到 2025 年將達到 27.1 億美元，到 2033 年將達到 47.3 億美元，在預測期（2026-2033 年）內，複合年成長率為 7.2%。

受醫療機構研發投入不斷增加的推動，重組蛋白市場預計將迎來顯著成長。重組蛋白的建構過程包括分離目標蛋白的轉錄區，並將其克隆到表達質體載體中，主要在微生物、酵母菌或培養的動物細胞中進行。重組蛋白在蛋白質-蛋白質交互作用研究中發揮關鍵作用，並在清潔劑、化妝品、營養保健品、診斷、疫苗和治療等多個領域有廣泛的應用。慢性病發病率的上升以及監管機構為遏制病毒感染而加強監管，是推動市場發展的主要因素。這些因素的綜合作用預計將刺激對重組蛋白的需求激增，為市場帶來巨大的發展機會。

重組蛋白市場促進因素

受製藥和生技公司研發投入增加的推動，重組蛋白市場正經歷顯著成長。資金的增加刺激了創新，並促進了新型治療方法的開發。此外，監管環境的改善也為血友病和各種出血性疾病等罕見疾病帶來了許多機會。研發活動的活性化，加上監管環境的變化，正在推動重組蛋白生產技術的進步，為患者拓展治療選擇，並推動市場發展。最終，這些因素共同創造了有利於科學進步和治療創新的環境。

重組蛋白市場限制因素

重組蛋白市場面臨一項重大挑戰：眾多主要企業在相對較小的市場中提供類似產品，導致激烈的價格競爭。這種市場飽和導致價格下行壓力，因為各公司都在努力保持競爭力並吸引消費者。因此，價格下跌阻礙了市場成長潛力，使企業難以獲得足夠的利潤率。在這種環境下，企業需要在產品策略中平衡品質和成本控制，從而限制了整個重組蛋白產業的發展。

重組蛋白市場趨勢

重組蛋白市場正呈現出顯著的發展趨勢，這主要得益於抗體領域的快速成長。抗體在治療、診斷和研究等多種應用領域中的應用日益廣泛，而生物技術的進步正是推動這一快速成長的關鍵因素。高效的抗體篩選和設計技術，以及先進的表達系統，使得大規模生產成為可能，進一步促進了抗體的大規模生產。各公司正積極投資研發，以充分發揮重組抗體的潛力。與傳統蛋白相比，重組抗體具有更高的特異性和更低的副作用。這種日益成長的需求預示著重組蛋白，尤其是在製藥和生物製藥領域，擁有廣泛的發展前景。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Bio-Techne（US）
Thermo Fisher Scientific Inc.（US）
Merck KGaA（Germany）
Danaher Corporation（US）
Abnova Corporation（Taiwan）
BioLegend Inc（US）
Bio-Rad Laboratories, Inc.（US）
BPS Bioscience, Inc.（US）
Enzo Biochem Inc.（US）
GenScript（China）
Miltenyi Biotec BV & Co. KG（Germany）
Proteintech Group, Inc.（US）
Sino Biological Inc.（China）
ACROBiosystems Group（US）
Aviva Systems Biology Corporation（US）
Sartorius CellGenix GmbH（Germany）
Icosagen（US）
Neuromics（US）
ProSpec-Tany TechnoGene Ltd.（Israel）
ProteoGenix SAS（France）

簡介目錄

Product Code: SQMIG35H2039

Recombinant Protein Market size was valued at USD 2.53 Billion in 2024 and is poised to grow from USD 2.71 Billion in 2025 to USD 4.73 Billion by 2033, growing at a CAGR of 7.2% during the forecast period (2026-2033).

The recombinant protein market is set for significant growth driven by increased investment from healthcare organizations in research and development. The process involves isolating coding sequences of target proteins and cloning them into expression plasmid vectors, primarily utilizing microbes, yeast, or cultured animal cells. Recombinant proteins play a crucial role in studying protein-protein interactions and have diverse applications across various sectors, including detergents, cosmetics, food supplements, diagnostics, vaccinations, and therapies. The rising incidence of chronic diseases and the expansion of regulatory bodies aiming to mitigate viral infections are key contributors to the market's advancement. As these factors align, the demand for recombinant proteins is expected to soar, positioning the market for substantial opportunities.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Protein market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Protein Market Segments Analysis

Global Recombinant Proteins Market is segmented by Product, Application, Host cell, End User and region. Based on Product, the market is segmented into Cytokines & Growth Factors (Interferons (IFNs), Interleukins (ILs), Others), Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes (Kinases, Metabolic Enzymes, Others), Recombinant Regulatory Proteins, Hormones, Others. Based on Application, the market is segmented into Drug Discovery & Development (Biologics, Vaccines, Cell & Gene Therapy), Biopharmaceutical Production, Research (Academic Research, Biotechnology Research), Diagnostics, and Others. Based on Host cell, the market is segmented into Mammalian Systems, Insect Cells, Yeast & Fungi, Bacterial Cells, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical, Academic Research Institutes, Contract Research Organizations, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Recombinant Protein Market

The Recombinant Protein market is experiencing significant growth driven by the rising investments in research and development from pharmaceutical and biotechnology companies. Enhanced funding has facilitated innovation, enabling the development of novel therapies. Additionally, an increase in regulatory requirements has opened up numerous opportunities for targeting rare diseases, such as hemophilia and various bleeding disorders. This combination of heightened R&D activity and the regulatory landscape is paving the way for advancements in recombinant protein production, thereby expanding treatment options for patients and propelling the market forward. As a result, the landscape is becoming increasingly conducive to scientific progress and therapeutic innovation.

Restraints in the Recombinant Protein Market

The recombinant protein market faces significant challenges due to intense price competition arising from numerous key players entering a relatively confined market with similar product offerings. This saturation leads to a downward pressure on pricing, as companies strive to attract consumers while maintaining competitiveness. Consequently, as prices decrease, the potential for market growth may be hindered, making it difficult for companies to achieve substantial profit margins. This environment creates constraints on the overall development of the recombinant protein sector, as businesses navigate the balance between maintaining quality and lowering costs in their product strategies.

Market Trends of the Recombinant Protein Market

The recombinant protein market is witnessing a significant trend driven by the rapid growth of the antibody segment, which is increasingly being adopted across diverse applications such as therapeutics, diagnostics, and research. This surge is propelled by advancements in biotechnology that facilitate the efficient selection and engineering of antibodies, enabling their large-scale production through sophisticated expression systems. Companies are actively investing in research and development to harness the potential of recombinant antibodies, which offer enhanced specificity and reduced side effects compared to traditional proteins. This burgeoning interest indicates a robust future for recombinant proteins, particularly in the pharmaceutical and biopharmaceutical sectors.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Pricing Analysis
Technology Analysis
Value Chain Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Analysis
PESTEL Analysis

Recombinant Proteins Market, By Product

Market Overview
Cytokines & Growth Factors
- Interferons (IFNs)
- Interleukins (ILs)
- Others
Antibodies
Immune Checkpoint Proteins
Virus Antigens
Enzymes
- Kinases
- Metabolic Enzymes
- Others
Recombinant Regulatory Proteins
Hormones
Others

Recombinant Proteins Market, By Application

Market Overview
Drug Discovery & Development
- Biologics
- Vaccines
- Cell & Gene Therapy
Research
- Academic Research
- Biotechnology Research
Biopharmaceutical Production
Diagnostics
Other Applications

Recombinant Proteins Market, By Host Cell

Market Overview
Mammalian Systems
Insect Cells
Yeast & Fungi
Bacterial Cells
Other Host Cells

Recombinant Proteins Market, By End User

Market Overview
Pharmaceutical & Biopharmaceutical Companies
Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Other End Users

Recombinant Proteins Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Bio-Techne (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abnova Corporation (Taiwan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioLegend Inc (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BPS Bioscience, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Enzo Biochem Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GenScript (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Miltenyi Biotec B.V. & Co. KG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Proteintech Group, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sino Biological Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ACROBiosystems Group (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aviva Systems Biology Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sartorius CellGenix GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Icosagen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neuromics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProSpec-Tany TechnoGene Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ProteoGenix S.A.S (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments